FDA Approves Blood Test for Early Alzheimer’s Risk Detection Using Neutrophil Inflammation Marker
The FDA approved the Lumipulse G pTau217/ß-Amyloid 1-42 blood test for early Alzheimer’s detection in adults 55+ with cognitive decline.
Read More
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Alzheimer’s Disease
Hydrogen Sulfide Gas from CSE Protein Emerges as Potential Alzheimer’s Treatment Target
Johns Hopkins researchers identify CSE enzyme and hydrogen sulfide as potential targets to prevent Tau protein-related Alzheimer’s progression.
Read More